Ultrasound-Responsive Cyclodextrin Delivery as Therapy for Atherosclerosis
Atherosclerosis is a major cause of mortality and morbidity worldwide. Left undiagnosed and untreated, atherosclerotic plaques can rupture and cause
Tag: atherosclerosis
CD-enabled, reactive oxygen species (ROS)-responsive size-reducible nanoassemblies for deeper atherosclerotic plaque penetration and enhanced macrophage-targeted drug delivery
Nanoparticle-based therapeutics represent potential strategies for treating atherosclerosis; however, the complex plaque microenvironment poses a barrier for nanoparticles to target
Poly-β-cyclodextrin Supramolecular Nanoassembly with a pH-Sensitive Switch Removing Lysosomal Cholesterol Crystals for Antiatherosclerosis
Cholesterol crystals (CCs), originally accumulating in the lysosome of cholesterol-laden cells, can aggravate the progression of atherosclerosis. β-cyclodextrin (CD) is
Beta-Cyclodextrin/L-Arginine/Au Nanomotors for Atherosclerosis
Most of the current non-pharmacological treatment strategies for atherosclerosis (AS) suffer from poor penetration into the plaque and only aim
Underdog Closes $10M Financing Round – the next cyclodextrin can be developed further as active
Underdog Pharmaceuticals, a key investment of Michael Greve’s rejuvenation biotech VC Kizoo, has closed a $10 million round of capital.
Underdog Pharmaceuticals Awarded ‘Innovation Passport’ by UK Regulators
Underdog Pharmaceuticals, Inc. (Underdog), a pre-clinical stage pharmaceutical company focusing on the treatment and reversal of age-related diseases, has been
Cyclodextrin dimers: a versatile approach to optimizing encapsulation and their application to therapeutic extraction of toxic oxysterols
A novel class of specifically engineered, dimerized cyclodextrin nanostructures was developed for the encapsulation of toxic biomolecules such as 7-ketocholesterol
Cyclodextrin dimers to treat atherosclerotic plaques by targeting various forms of cholesterol
SENS Research Foundation (USA, California) filed a PCT patent application (WO2020142716) that was recently published. In the invention, a new class
Underdog Pharmaceuticals Announces MD.USE Partnership and Technology Acquisition
Underdog Pharmaceuticals, Inc., a pharmaceutical company designing engineered cyclodextrins to address atherosclerosis and other serious diseases of aging, has completed
Is CD shuttle or sink for cholesterol?
A Chinese group has recently published [1] their interesting findings: in atherosclerosis β-CD (probaly methyl beta-cyclodextrin, but not specified) was